ARTICLE | Clinical News

Desmopressin Peptide Formulation hydration buccal tablet: Phase I

October 8, 2001 7:00 AM UTC

COB said that its Desmopressin Peptide Formulation produced detectable blood levels of Desmopressin in the majority of patients at numerous time points over the 24-hour dosing interval. The 8-patient kinetics trial compared the product to intravenous desmopressin. The product uses COB’s Bio-Adhesive Delivery System (BDS) as a progressive hydration buccal tablet for small chain peptide absorption through the transmucosal membrane ...